Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ascletis to sell Roche’s HCV medicine danoprevir in greater China

Executive Summary

Oncology and infectious disease spec pharma Ascletis Inc. has received rights in China, Taiwan, Hong Kong, and Macau to develop, manufacture, and market Roche’s direct-acting antiviral agent danoprevir, which is in Phase II for hepatitis C virus (HCV). Ascletis will be calling the compound by the lab code ASC08.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies